Nanobiosym
MA - CambridgeBiotechnology
Focus: Nanobiosym is a Cambridge-based nanobiotech company founded in 2019, specializing in nanoscale biotechnology innovation. The company is early-stage with 34 active job openings and appears focused on instrument and diagnostic development.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Open Jobs
34+60 this month
Hot — 60 jobs added in 30d
Net +60 (60 new, 0 removed). Aggressive expansion phase.
Should You Work at Nanobiosym?
AI assessmentNanobiosym is a high-risk, high-upside early-stage nanotech play best suited for technologists and founders willing to build foundational IP without near-term product/revenue visibility.
Why Work Here
- Heavy hiring in IT (6 roles) and Instrument Development (3 roles) signals active product development and tech modernization.
- CLIA lab operations (4 openings) indicate diagnostic/testing capability buildout with regulatory pathway clarity.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Nanobiosym
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.